Genomic Grade Index predicts postoperative clinical outcome of GIST

p16 Expression Differentiates High-Risk Gastrointestinal Stromal Tumor and Predicts Poor Outcome

(2015) Michael Schmieder et al.   NEOPLASIA

An Integrated Study of Aberrant Gene Copy Number and Gene Expression in GIST and LMS

(2014) Da Yang et al.   TECHNOLOGY IN CANCER RESEARCH & TREATMENT

Natural History of Imatinib-naive GISTs

(2011) Sabrina Rossi et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Navigating Risk Stratification Systems for the Management of Patients With GIST

(2011) Shreyaskumar Patel   ANNALS OF SURGICAL ONCOLOGY

The Management of Gastrointestinal Stromal Tumors: A Model for Targeted and Multidisciplinary Therapy of Malignancy

(2011) Heikki Joensuu et al.   Annual Review of Medicine

Mitotic Checkpoints and Chromosome Instability Are Strong Predictors of Clinical Outcome in Gastrointestinal Stromal Tumors

(2011) P. Lagarde et al.   CLINICAL CANCER RESEARCH

Aberrant DNA methylation associated with aggressiveness of gastrointestinal stromal tumour

(2011) Yasuyuki Okamoto et al.   GUT

Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts

(2011) Heikki Joensuu et al.   LANCET ONCOLOGY

Expression level of the mitotic checkpoint protein and G2–M cell cycle regulators and prognosis in gastrointestinal stromal tumors in the stomach

(2011) Aya Fujita et al.   VIRCHOWS ARCHIV

Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2010) P. G. Casali et al.   ANNALS OF ONCOLOGY

Cyclin H expression is increased in GIST with very-highrisk of malignancy

(2010) Julian Dorn et al.   BMC CANCER

Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors

(2010) Antti Ylipää et al.   CANCER

Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis

(2010) Gabriella Arne et al.   INTERNATIONAL JOURNAL OF CANCER

The GIST paradigm: lessons for other kinase-driven cancers

(2010) Cristina R Antonescu   JOURNAL OF PATHOLOGY

A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number

(2010) Annalisa Astolfi et al.   LABORATORY INVESTIGATION

ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours

(2010) Ping Chi et al.   NATURE

Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity

(2010) Frédéric Chibon et al.   NATURE MEDICINE

Functional features of gene expression profiles differentiating gastrointestinal stromal tumours according to KITmutations and expression

(2009) Jerzy Ostrowski et al.   BMC CANCER

Cell Cycle/Apoptosis Molecule Expression Correlates with Imatinib Response in Patients with Advanced Gastrointestinal Stromal Tumors

(2009) S. Romeo et al.   CLINICAL CANCER RESEARCH

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

(2009) Ronald P DeMatteo et al.   LANCET

Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis

(2009) Jason S Gold et al.   LANCET ONCOLOGY

Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor

(2009) L. Rink et al.   MOLECULAR CANCER THERAPEUTICS

Sixteen-Kinase Gene Expression Identifies Luminal Breast Cancers with Poor Prognosis

(2008) P. Finetti et al.   CANCER RESEARCH

Risk stratification of patients diagnosed with gastrointestinal stromal tumor

(2008) Heikki Joensuu   HUMAN PATHOLOGY

Distinct Gene Expression–Defined Classes of Gastrointestinal Stromal Tumor

(2008) Umio Yamaguchi et al.   JOURNAL OF CLINICAL ONCOLOGY

Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group

(2008) Michael C. Heinrich et al.   JOURNAL OF CLINICAL ONCOLOGY

Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor

(2008) Michael C. Heinrich et al.   JOURNAL OF CLINICAL ONCOLOGY

Loss of 9p leads to p16INK4A down-regulation and enables RB/E2F1-dependent cell cycle promotion in gastrointestinal stromal tumours (GISTs)

(2008) F Haller et al.   JOURNAL OF PATHOLOGY

Increased KIT signalling with up-regulation of cyclin D correlates to accelerated proliferation and shorter disease-free survival in gastrointestinal stromal tumours (GISTs) withKITexon 11 deletions

(2008) F Haller et al.   JOURNAL OF PATHOLOGY

Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST)

(2007) Ronald P. DeMatteo et al.   CANCER